Audentes Therapeutics, an Astellas company developing AAV-based genetic medicines, is investing $109 million to build a new gene therapy manufacturing facility in North Carolina.
The 135,000 sq ft state-of-the-art plant is expected to be operational in 2021. The company said it plans to create over 200 news jobs in the area.
“Our investment in large-scale manufacturing has always been a cornerstone of our strategy to develop and ultimately deliver our important genetic medicines to patients as rapidly as possible,” said Natalie Holles, President and CEO of Audentes.
“This new facility in Sanford will support the next phase of our growth as we establish a robust, global supply chain and expand our therapeutic and geographic scope as a part of the Astellas group of companies.”